baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Coherus BioSciences Inc/ US19249H1032 /

2024-04-23 10:15:00 PM	Chg. 0.0000	Volume	Bid1:43:27 AM	Ask1:43:27 AM	High	Low
2.1800USD	0.00%	811,796 Turnover: 1.65 mill.	2.1600Bid Size: 1,600	2.2500Ask Size: 4,200	2.2450	2.1000

GlobeNewswire 04-08 Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual ...

GlobeNewswire 03-13 Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Bu...

GlobeNewswire 03-05 Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

GlobeNewswire 03-04 Coherus Completes Divestiture of Ophthalmology Franchise

GlobeNewswire 03-04 Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leader...

GlobeNewswire 02-23 Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire 02-21 Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery S...

GlobeNewswire 02-21 Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

GlobeNewswire 02-05 Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

GlobeNewswire 01-22 Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All ...

GlobeNewswire 01-22 Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US m...

GlobeNewswire 01-18 Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Ant...

GlobeNewswire 01-03 Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 01-03 Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief...

GlobeNewswire 01-02 Coherus Announces U.S. Launch of LOQTORZI™

GlobeNewswire 2023-12-26 Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery...

GlobeNewswire 2023-12-22 Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire 2023-12-11 Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi)...

GlobeNewswire 2023-12-07 Coherus BioSciences Announces CFO Transition Plans

GlobeNewswire 2023-12-06 Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, ...

GlobeNewswire 2023-11-28 Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JU...

GlobeNewswire 2023-11-13 Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire 2023-11-06 Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

GlobeNewswire 2023-11-03 Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Societ...

GlobeNewswire 2023-11-03 Coherus BioSciences to Participate at Upcoming November Investor Conferences

Coherus BioSciences Inc/ US19249H1032 /

If you wish to receive reply to your feedback, please provide your email address.